daVIZta, Inc.

daVIZta, Inc. is a data analytics company focused on enhancing therapy commercialization and access management for the life sciences sector through innovative solutions and integrated platforms. Founded in 2010 and headquartered in Philadelphia, US, daVIZta, Inc. provides data analytics solutions to the life sciences industry.

In March 2019, the company became a portfolio entity of Accel-KKR when it was acquired by IntegriChain. The acquisition was finalized in November 2019, marking a strategic pivot for IntegriChain's service offerings. The current CEO information is not provided. daVIZta, Inc.

specializes in comprehensive data and analytics solutions for the life sciences industry, particularly in therapy commercialization and access management. Through their core offering, the ICyte Platform, they deliver extensive analytics, consulting, and business processes to assist pharmaceutical manufacturers in navigating market access. Their services address vital operational challenges including gross-to-net calculations, government pricing, and contract management, with a client base comprising over 160 life science manufacturers ranging from startups to major enterprises. The company has a substantial presence in North America and is expanding into European and select Asian markets.

daVIZta, Inc. generates revenue through a subscription-based model, allowing clients to utilize their ICyte Platform for various analytics and managed services. Contracts typically span one year, offering tiered access based on the scale of services utilized, including consulting and analytics modules. A considerable portion of revenue stems from services related to gross-to-net automation and pricing strategies, reflecting their strong position in the life sciences data analytics market.

Following the acquisition by IntegriChain in November 2019, daVIZta, Inc. aims to leverage the financial backing to enhance and expand its product offerings. The company is focusing on developing new features for the ICyte Platform and plans to broaden its market presence in Europe and Asia by 2022. The funding received during the acquisition is intended to bolster these initiatives and support the introduction of innovative products designed to meet evolving client needs.